MYCN and neuroblastoma: We found that the FDA-approved drug dipyridamole, an inhibitor of the SLC29 family of nucleoside transporters [48–50], markedly enhanced the antiproliferative activity of DHODH inhibitors in MYCN-amplified neuroblastoma cell lines in the presence of supplemental uridine or high serum content.